Showing results (491-500 of 587) with videos related to
Sort By:
Pageof 59
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 8, 2020
Randomized Phase II Trial Evaluating Treatment with EGFR-TKI Associated with Antiestrogen in Women with Nonsquamous Advanced-Stage NSCLC: IFCT-1003 LADIE TrialJulien Mazieres, Fabrice Barlesi, Isabelle Rouquette, et al.Lung Cancer (Auckland, N.Z.)|June 28, 2024
Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus SurveySai-Hong Ignatius Ou, Xiuning Le, Misako Nagasaka, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2025
Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 StudyJacob Sands, Myung-Ju Ahn, Aaron Lisberg, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 25, 2019
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 StudiesHyun Cheol Chung, Sarina A Piha-Paul, Jose Lopez-Martin, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 30, 2026
Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief ReportHidetoshi Hayashi, Byoung Chul Cho, David R Spigel, et al.The New England Journal of Medicine|November 22, 2019
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLCSuresh S Ramalingam, Johan Vansteenkiste, David Planchard, et al.NPJ Precision Oncology|February 26, 2024
Genomic landscape of liquid biopsy mutations in TP53 and DNA damage genes in cancer patientsDamien Vasseur, Ahmadreza Arbab, Fabiola Giudici, et al.The Journal of Clinical Investigation|December 28, 2018
PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancerRoman M Chabanon, Gareth Muirhead, Dragomir B Krastev, et al.JTO Clinical and Research Reports|June 29, 2026
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, EGFR Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY TrialNicolas Girard, Jonathan Goldman, Shun Lu, et al.Future Oncology (London, England)|March 4, 2026
Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or HER2-mutant solid tumorsAlison M Schram, John J Park, Antoine Italiano, et al.Pageof 59